Alejandro Rojas | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Alejandro Rojas | Immunology Cellular Interactions | Best Researcher Award

Assist. Prof. Dr. Alejandro Rojas | Austral University of Chile | Germany

Dr. Alejandro Alfredo Rojas Fernández is a distinguished Chilean molecular biotechnologist and neuroscientist, currently serving as CEO of Berking Theranostics UG in Hamburg, Germany, and Assistant Professor at the Universidad Austral de Chile. With over two decades of research spanning neurodegeneration, immunology, and viral pathogenesis, Dr. Rojas-Fernández has emerged as a leading expert in molecular diagnostics and theranostics. His innovative work has significantly impacted global health, notably through his contributions to SARS-CoV-2 research and senolytic therapies. A dual academic and entrepreneur, he bridges fundamental science and clinical application, actively publishing in top-tier journals such as Nature Aging, Molecular Psychiatry, and Journal of Cell Biology. Fluent in interdisciplinary collaboration, his efforts have been internationally recognized with multiple honors. With a passion for translational science, Dr. Rojas-Fernández continues to inspire the next generation of biomedical innovators through mentorship and leadership in biotechnology and neuroscience.

Publication Profile:

Orcid

Education:

Dr. Alejandro Rojas-Fernández earned his PhD in Biology from the University of Konstanz, Germany (2006–2010), where his research focused on the regulation of Hdm2/HdmX-mediated ubiquitination and neddylation—mechanisms central to protein stability and cancer biology. Prior to his doctorate, he completed his engineering degree in Molecular Biotechnology (2004–2005) and his B.Sc. in Molecular Biotechnology Engineering (2000–2004) at the Faculty of Sciences, University of Chile—one of Latin America’s leading research institutions. His multidisciplinary education integrates molecular biology, neurobiology, immunology, and translational medicine, equipping him with the foundational and advanced tools to tackle complex biomedical challenges. Dr. Rojas-Fernández’s academic training has been marked by academic excellence and international mobility, enabling him to collaborate and lead research projects across Europe and Latin America.

Experience:

Dr. Rojas-Fernández brings over 20 years of experience in translational biomedical research, academia, and biotech innovation. As CEO of Berking Theranostics UG, he spearheads the development of personalized diagnostic platforms and therapeutics, with a focus on neurodegenerative and inflammatory diseases. In his role as Assistant Professor at Universidad Austral de Chile (20% appointment), he leads the Medical Biotechnology Laboratory within the Centre for Interdisciplinary Studies on the Nervous System (CISNe), contributing to scientific training and cutting-edge research. He previously trained and collaborated at institutions such as the University of Dundee, University of Queensland, and University of Constance, advancing molecular mechanisms of SUMOylation, proteostasis, inflammasome biology, and viral-host interactions. His interdisciplinary expertise allows him to translate complex cellular insights into tangible clinical applications, and his leadership has resulted in high-impact publications, product pipelines, and strategic biotech partnerships in Europe and Latin America.

Awards and Honors:

Dr. Rojas-Fernández has received multiple prestigious honors recognizing his innovative biomedical research. In February 2025, he was named “Innovator of the Month” by Hamburg Invest for groundbreaking biotech contributions in Germany. He was awarded the Medal of the City of Valdivia for his vital role in controlling the SARS-CoV-2 pandemic, one of the highest local honors in Chile. Additionally, he received the 2nd of October Medal for Science and Innovation, recognizing his scientific leadership in Chile’s Los Ríos region. These accolades underscore his impact on global public health, neurodegenerative research, and biotechnology entrepreneurship. His consistent recognition reflects a career dedicated to translational excellence, fostering international collaboration, and advancing science for the benefit of society. His scientific achievements continue to inspire innovation and interdisciplinary approaches within the global scientific community.

Research Focus:

Dr. Alejandro Rojas-Fernández’s research centers on cellular stress responses, ubiquitin/SUMO signaling, neurodegeneration, and host-pathogen interactions. A core focus is the molecular crosstalk between autophagy, protein quality control, and inflammasome activation in brain and immune cells. He has made significant advances in understanding the effects of SARS-CoV-2 on microglia, mechanisms of senescence in aging brains, and nanobody-based viral neutralization. His studies also explore the intersection of endoplasmic reticulum stress and neurodegenerative pathways, using high-content screening and proteomics to uncover therapeutic targets. He actively translates molecular insights into diagnostics and theranostic tools, positioning him at the forefront of personalized medicine. As CEO of a biotech startup, he is developing platforms that integrate biomarker discovery with AI for neuroinflammation profiling. His research bridges fundamental biology and clinical applications, promoting innovative therapies for Alzheimer’s, Parkinson’s, cancer, and viral infections.

Publications Top Notes: 

  1. Negative Modulation of Macroautophagy by Stabilized HERPUD1… – Front Cell Dev Biol, 2022

  2. SARS-CoV-2 drives NLRP3 inflammasome activation in human microglia… – Mol Psychiatry, 2022

  3. The p97/VCP segregase is essential for arsenic-induced degradation of PML… – J Cell Biol, 2023

  4. Lack of Parkinsonian Pathology after Proteasome Inhibitor Injection… – Front Aging Neurosci, 2021

  5. NSPA modulates postsynaptic NMDAR stability… – BMC Biol, 2020

  6. Role of PSMD14 in Golgi-to-ER transport and APP processing – Cells, 2020

  7. WDR90 in NLRC4 inflammasome and Salmonella resistance – Dev Comp Immunol, 2019

  8. Proteomic identification of APC interaction partners – Mol Cancer Res, 2019

  9. DHX15 regulates CMTR1-dependent gene expression – Life Sci Alliance, 2018

  10.  Membrane ruffling by polarized stim1 and orai1 – Sci Reports, 2017

Conclusion:

Dr. Alejandro Alfredo Rojas Fernández stands out as a pioneering researcher who consistently delivers scientifically rigorous, socially impactful, and clinically relevant work. His career spans critical sectors—basic research, applied biotechnology, and public health—making him a model example of the translational scientist. With accolades from both European and Latin American institutions and a track record of high-impact publications, Dr. Rojas exemplifies what it means to be a globally relevant and community-driven scientist. His work during the COVID-19 pandemic, innovations in molecular neuroscience, and leadership in therapeutic biotechnology underscore his immense value to the global research community. In conclusion, he is not only a suitable but a highly deserving candidate for the Best Researcher Award.

Herbeuval Jean-Philippe | Immunology Cellular Interactions | Best Innovator Award

Published on by Cell Biologist

Dr. Herbeuval Jean-Philippe | Immunology Cellular Interactions | Best Innovator Award

Dr. Herbeuval Jean-Philippe | CNRS | France

Jean-Philippe Herbeuval is a French immunologist and CNRS Director of Research, renowned for pioneering contributions to translational immunology and biomedical innovation. A PhD holder in immuno-oncology, he completed a prestigious Fogarty Fellowship at the NIH, USA, where he earned the Norman P. Salzman Award. He founded and leads the CBMIT team at Université Paris Cité, integrating immunology, virology, and chemistry for therapeutic discovery. Herbeuval has launched two biotech companies: Ermium Therapeutics, based on anti-interferon therapies, and Elyris Pharma, centered on PDK1 as a novel anti-inflammatory target. With 9 patents (3 licensed), €8.8M in research funding, and >70 publications (h-index 28), his innovations span diagnostics to therapeutics. He also contributes to policy and innovation strategy through national and international committees. Recognized for his vision, leadership, and mentorship, Herbeuval exemplifies the intersection of academic research and impactful biotechnology entrepreneurship.

Publication Profile:

Google Scholar

✅ Strengths for the Award:

  1. Exceptional Innovation in Immunology & Therapeutics

    • Discovered key therapeutic targets such as CXCR4 and PDK1.

    • Founded Ermium Therapeutics (2019) and Elyris Pharma (2024), securing over €12M in funding.

    • Holds 9 patents, with 3 already licensed — a key indicator of translational success.

  2. Proven Scientific Leadership

    • Director of Research (CNRS), Head of CBMIT at Université Paris Cité.

    • Established and led multiple interdisciplinary research teams and platforms (Cyto2BM, CBMIT).

    • Supervised 10 PhD students, 7 postdocs, and over 18 master’s students, many of whom reached elite positions.

  3. High-Impact Research Output

    • 70+ publications, including high-citation studies on interferon signaling in HIV.

    • Over 3,500 citations, h-index: 28 — showing strong impact and visibility.

  4. Strong National and International Recognition

    • Winner of the prestigious i-Lab National Innovation Prize (France, 2019).

    • Invited speaker at over 24 international conferences; reviewer for Nature Medicine and PNAS.

    • Advisor for funding agencies across the US (NIH), UK (MRC), China, and Brazil.

  5. Valuable Public and Government Engagement

    • CNRS Innovation Ambassador (2024) and expert for multiple national programs (ANRS, Campus France).

    • Actively engages in public science communication (TV, radio, press).

🔧 Areas for Improvement:

  1. Scaling Global Industry Impact

    • While Ermium and Elyris are high-potential, further proof of market adoption and therapeutic success will solidify his innovation leadership globally.

  2. Broader Patent Commercialization

    • More patents could potentially be moved from licensing to full-scale clinical trials or product development phases.

  3. Diversity of Therapeutic Areas

    • While the focus on interferon biology and immunomodulation is powerful, broader expansion into other disease domains (e.g., neuroinflammation, metabolic syndromes) could enhance reach.

🎓 Education:

Jean-Philippe Herbeuval earned his PhD in immuno-oncology in 2001 from Université Jean Monnet, Saint-Étienne, working under the INSERM network. He then pursued a highly competitive five-year Fogarty Postdoctoral Fellowship at the National Institutes of Health (NIH), USA, under Dr. Gene Shearer, focusing on the antiviral response to HIV. During this time, he earned multiple prestigious awards including the Norman P. Salzman Award and an NIH Young Scientist Cash Award. Upon returning to France, he secured a CNRS Junior PI position in 2006 and received his Habilitation to Direct Research (HDR) in 2008 from Université Paris Descartes. His rapid career progression continued with his appointment as Director of Research (2nd class) in 2013 and promotion to 1st class in 2019 at CNRS UMR8601. His educational path reflects an exceptional blend of scientific rigor, international exposure, and leadership in innovation.

💼 Experience:

Jean-Philippe Herbeuval brings over two decades of distinguished experience at the interface of academic research and biotech innovation. Starting with his postdoctoral fellowship at NIH (2001–2006), he led groundbreaking studies on interferon responses in HIV. Since 2006, he has served within CNRS, creating and leading the CBMIT interdisciplinary team. He established the Cyto2BM core facility and spearheaded multiple translational projects. As scientific founder of Ermium Therapeutics (2019) and Elyris Pharma (2024, in progress), he has successfully attracted venture capital and secured technology transfer agreements. His strategic involvement extends to national innovation committees (ANRS, CNRS, Campus France) and advisory roles. He has trained over 35 researchers and supervised major national/international grants. Notably, he combines deep scientific insight with an entrepreneurial mindset, as shown by his participation in Deeptech Founders and RISE programs. His experience spans leadership, translational science, investment negotiations, and scientific mentoring.

🔬 Research Focus:

Jean-Philippe Herbeuval’s research is centered on translational immunology, particularly type I interferons, autoinflammatory pathways, and host-pathogen interactions. His work explores immune dysregulation in infectious diseases such as HIV, SARS-CoV-2, dengue, and influenza, with a special focus on the immune-modulatory roles of dendritic cells and apoptotic pathways. He has identified novel therapeutic targets including CXCR4 and PDK1, leading to two biotech start-ups and multiple patents. His interdisciplinary CBMIT team integrates immunology, virology, medicinal chemistry, and computational modeling to develop innovative therapeutic strategies and biomarkers. He has a keen interest in immunomodulation, therapeutic interference with IFN pathways, and discovery of druggable checkpoints in innate immunity. With over 70 peer-reviewed publications, his scientific output has shaped current understanding of immune pathogenesis and opened new avenues for therapy in inflammatory and infectious diseases. His approach bridges fundamental research with practical applications in drug discovery and biotech development.

📚 Publications Top Notes:

  1. 🧬 HIV inhibits CD4+ T-cell proliferation by inducing indoleamine 2,3-dioxygenase in plasmacytoid dendritic cells

  2. ⚰️ CD4+ T-cell death induced by infectious and noninfectious HIV-1: role of type 1 interferon–dependent, TRAIL/DR5-mediated apoptosis

  3. 🚻 Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-α production in women

  4. 🧪 HIV-1 immunopathogenesis: how good interferon turns bad

  5. 🔄 Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells

  6. 🧠 Differential expression of IFN-α and TRAIL/DR5 in lymphoid tissue of progressor vs. nonprogressor HIV-1-infected patients

  7. 🧟 HIV turns plasmacytoid dendritic cells into TRAIL-expressing killer pDC via TLR7-induced IFN-α

  8. 🧬 Regulation of TRAIL on primary CD4+ T cells by HIV-1: role of plasmacytoid dendritic cells

  9. 💉 TRAIL in HIV-1–infected patients and its production by antigen-presenting cells

  10. 🧫 Recruitment of STAT3 for production of IL-10 by colon carcinoma cells induced by macrophage-derived IL-6

🧾 Conclusion:

Dr. Jean-Philippe Herbeuval stands out as a highly qualified and deserving candidate for the Best Innovator Award. His rare combination of scientific excellence, translational innovation, entrepreneurial leadership, and mentorship places him in the top tier of biomedical innovators. His work not only bridges science and industry but also directly contributes to addressing global health challenges. Continued support and recognition of his efforts will likely catalyze further innovation in therapeutic immunology.

Xiaoyan Wang | Immunology Cellular Interactions | Best Researcher Award.

Published on by Cell Biologist

Ms. Xiaoyan Wang | Immunology Cellular Interactions | Best Researcher Award

Ms. Xiaoyan Wang, Fudan University, China

Dr. Xiaoyan Wang is a postdoctoral fellow at Fudan University with a strong foundation in both clinical and basic cardiovascular research. She holds a PhD in Cardiology from Fudan University and is currently advancing her expertise through the Global Clinical Scholars Research Training Program at Harvard Medical School. Her academic journey spans over a decade of progressive education and clinical experience, complemented by multiple high-impact publications. She actively contributes to scholarly communities as an editor for AME Clinical Trials Review and the organizer of an academic communication club. Dr. Wang’s work bridges immunology and cardiology, particularly in understanding immune mechanisms in cardiovascular diseases. She has received several prestigious fellowships and awards, reflecting her strong scientific rigor and leadership. With her multidisciplinary research background and international exposure, Dr. Wang is an emerging leader in cardiovascular translational research and a strong contender for the Best Researcher Award.

Publication Profile: 

Scopus

✅ Strengths for the Award:

  1. Strong Academic Foundation

    • Trained at top-tier institutions including Fudan University and currently enrolled at Harvard Medical School for global clinical research training.

    • Holds a PhD in Cardiology with a solid foundation in both clinical and basic research.

  2. Extensive Research Experience

    • Over a decade of research with a focus on ventricular remodeling, immune mechanisms in cardiovascular diseases, and non-coding RNAs.

    • Published in high-impact journals such as Signal Transduction and Targeted Therapy, Annals of Translational Medicine, and Heliyon.

  3. Recognized Expertise and Leadership

    • Awarded Postdoctoral Fellowship by CPSF and Super Postdoctoral Fellowship by Fudan University in 2023.

    • Section Editor at AME Clinical Trials Review and organizer of the “Excellent Academic Research Communication Club”.

  4. Interdisciplinary and Translational Focus

    • Combines clinical cardiology with molecular immunology, enhancing the translational potential of her research.

  5. Global Perspective

    • Active participation in international research forums like the Japanese Circulation Society, which reflects global relevance.

⚙️ Areas for Improvement:

  • Broader Collaboration: While her core work is well-recognized, expanding interdisciplinary and international collaborations could amplify her visibility.

  • Clinical Trial Leadership: Leading a multi-center clinical trial would significantly strengthen her clinical research credentials.

  • Grant Acquisition: More information on independently secured competitive research grants could further demonstrate leadership.

🎓 Education:

Dr. Xiaoyan Wang is currently enrolled in the Global Clinical Scholars Research Training Program (2024–2025) at Harvard Medical School, combining online and on-site learning. She earned her PhD in Cardiology at Fudan University’s Zhongshan Hospital (2016–2019), where she conducted basic research on ventricular remodeling under Prof. Yunzeng Zou, supported by national-level research funds. Earlier, she obtained her Master’s degree in clinical cardiology from Dalian Medical University (2013–2016), supervised by the esteemed Prof. Yaling Han. Her undergraduate training was completed at Fujian Medical University (2007–2012), where she laid the foundation for her clinical and academic career. Her education reflects a steady progression toward excellence in cardiovascular research, integrating both laboratory and patient-based studies. Dr. Wang’s cross-disciplinary and global educational background equips her with a unique perspective in translational medicine and scientific innovation.

🩺 Experience:

Dr. Xiaoyan Wang is a postdoctoral fellow at Fudan University (2023–present), where she continues her cardiovascular research under Prof. Yunzeng Zou and fosters academic exchange as the organizer of the “Excellent Academic Research Communication Club.” She also serves as a section editor for AME Clinical Trials Review (2024–present). Previously, she worked as a cardiologist at Shanghai Jiaotong University’s Ruijin Hospital (2022–2023) and as a cardiovascular specialist at Fudan University’s Zhongshan Hospital (2019–2022). Her clinical practice is complemented by a strong research portfolio and academic leadership. Dr. Wang’s diverse roles reflect her commitment to integrating clinical insight with research innovation. Her responsibilities span research coordination, patient care, publishing, and mentoring, positioning her as a clinician-scientist deeply embedded in academic medicine.

🏆 Awards and Honors:

Dr. Xiaoyan Wang has been recognized with several competitive awards that underscore her research excellence. In 2023, she received the Postdoctoral Fellowship Program of CPSF and was named a Super Postdoctoral Fellow at Fudan University—both high honors recognizing scientific innovation and impact. Her clinical insights and writing skills earned her third prize in the 8th “Buchang Cup” Young Physician Essay Contest (2019). She was also selected to present at the Late-Breaking Cohort Studies session at the Japanese Circulation Society (JCS) Annual Meeting in 2019, an indication of her work’s international relevance. These awards demonstrate her ability to balance rigorous clinical practice with pioneering research, making her a standout candidate for accolades like the Best Researcher Award.

🔬 Research Focus:

Dr. Wang’s research centers on the intersection of cardiology and immunology, with a special focus on ventricular remodeling, cGAS-STING signaling pathways, immune responses in myocardial infarction, and non-coding RNAs. Her work spans both basic and translational research, investigating the molecular mechanisms behind cardiovascular disease progression while aiming to identify therapeutic targets. She has explored the roles of Akt, β-arrestin-2, CaMKII, and immune gene signatures in heart failure and myocardial infarction. Dr. Wang’s research has practical clinical implications, informing diagnosis and prognosis in cardiovascular medicine. Through international collaborations and cutting-edge methodologies, she contributes to a deeper understanding of immune-cardiovascular crosstalk. Her publication track record and editorial roles affirm her impact in shaping current and future directions in cardiovascular research.

📚 Publications Top Notes: 

1️⃣ 🧬 The immune system in cardiovascular diseases: from basic mechanisms to therapeutic implications – Signal Transduction and Targeted Therapy (2025)
2️⃣ 🧠 The connection of immune response and cGAS-STING pathway in cardiovascular disease – International Journal of Biological Sciences (Revised)
3️⃣ 🧪 Left ventricular response in the transition from hypertrophy to failure… in mice with aortic regurgitation – Annals of Translational Medicine (2020)
4️⃣ 🩸 The diagnostic values of circulating miRNAs for hypertension and bioinformatics analysis – Bioscience Reports (2018)
5️⃣ 🚬 Galectin-3 inhibition alleviates cigarette smoke extract-induced EPC dysfunction by downregulating autophagy – Oxidative Medicine and Cellular Longevity (2019)
6️⃣ 🔁 Circular RNA in cardiovascular disease – Non-coding RNA Investigation (2017)
7️⃣ ❤️‍🔥 An Integrated Signature of Clinical Metrics and Immune-Related Genes as a Prognostic Indicator for STEMI Patient Survival – Heliyon (2024)

🧾 Conclusion:

Dr. Xiaoyan Wang is an exceptionally qualified candidate for the Best Researcher Award. Her research blends clinical relevance with molecular depth, showing a clear trajectory toward academic leadership in cardiovascular immunology. With a combination of high-impact publications, clinical acumen, and global training, she exemplifies the qualities this award seeks to honor. Minor expansions in clinical trial leadership and collaborative reach could further elevate her profile. Nevertheless, her current accomplishments already distinguish her as a top-tier emerging researcher.

Yong-Soo Bae | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Yong-Soo Bae | Immunology Cellular Interactions | Best Researcher Award

Prof. Dr. Yong-Soo Bae | Sungkyunkwan University | South Korea

Dr. Yong-Soo Bae is a distinguished immunologist and professor at the Department of Biological Science, Sungkyunkwan University, Korea. He currently serves as the Director of the SRC Center for Immune Research on Non-lymphoid Organs (CIRNOS). With over three decades of academic, clinical, and industry experience, Dr. Bae is internationally recognized for his pioneering research in immunology, virology, and vaccine development. His multidisciplinary contributions span academia, biotech innovation (as CEO/CTO of JW Creagene Inc.), and scientific leadership, including organizing global conferences and serving as editor-in-chief and president in numerous societies. His work focuses on immune modulation, cancer immunotherapy, and mucosal vaccines, which has led to influential publications in prestigious journals like Nature Communications, Science Advances, and Advanced Materials. Dr. Bae’s career reflects a commitment to innovation, collaboration, and education, making him a strong candidate for the Best Researcher Award.

Publication Profile:

Scopus

✅ Strengths for the Award

  1. Pioneering Research Leadership
    Dr. Bae has led groundbreaking research in immunology, particularly in immune regulation of non-lymphoid organs, vaccine development, and cancer immunotherapy. His leadership of the Center for Immune Research on Non-lymphoid Organs (CIRNOS) demonstrates his national influence in immune research.

  2. Extensive Scientific Contributions
    With over 18 high-impact publications in the past 3–4 years alone, including in top-tier journals like Nature Communications, Molecular Therapy, Science Advances, and Advanced Materials, Dr. Bae continues to push the boundaries of translational immunology and personalized medicine.

  3. International & Interdisciplinary Experience
    His training at Harvard Medical School, his professorships across Korean institutions, and leadership at JW Creagene Inc. showcase both academic and industrial impact.

  4. Scientific Community Engagement
    Roles such as Editor-in-Chief, society president, and organizer of global conferences (e.g., DC2012) reflect his commitment to advancing scientific dialogue and collaboration.

  5. Mentorship and Institutional Development
    Dr. Bae has contributed significantly to capacity building in Korea’s biomedical research landscape, mentoring junior scientists and shaping departmental growth.

⚠️ Areas for Improvement:

  1. Global Collaboration Visibility
    While his work is highly impactful in Korea and Asia, more joint publications with global institutions (e.g., NIH, Oxford, Karolinska) could further enhance international research influence.

  2. Patent and Commercial Output Reporting
    As former CEO/CTO of JW Creagene, elaborating on patented innovations or therapeutic products brought to market would strengthen the case for translational impact.

  3. Formal Recognition or Awards
    Inclusion of formal honors (e.g., national science medals, international society awards) would help quantify his recognition outside Korea.

  4. Consistent Author Disambiguation
    In some publications, author names appear as “Y.S. Bae” or “Yong-soo Bae.” Consistent use of a standardized author name across indexing platforms would help centralize his citation metrics and scholarly footprint.

 

🎓 Education:

Dr. Yong-Soo Bae’s academic journey began with a Bachelor’s and Master’s degree in Microbiology from Seoul National University in 1981 and 1983, respectively. His foundational training in microbiology laid the groundwork for his research trajectory in infectious disease and immunology. He earned his Ph.D. in 1990 from the University of Calgary, Alberta, Canada, in the Virology Division of the Department of Microbiology and Infectious Diseases, Faculty of Medicine. His doctoral research was crucial in shaping his interest in host-pathogen interactions and immune regulation. Dr. Bae’s international education experience has enabled him to blend Western and Eastern biomedical research paradigms, contributing to his ability to lead collaborative global projects and initiatives in immunotherapy and vaccine innovation.

💼 Experience:

Dr. Yong-Soo Bae’s professional career spans academia, research, and biotech leadership. He completed a postdoctoral fellowship at Dana-Farber Cancer Institute, Harvard Medical School (1991–1993), which enriched his expertise in cancer immunology. He held professorial roles at Hannam University (1993–2003) before joining Sungkyunkwan University in 2004, where he later became Department Chair and Distinguished Professor. Dr. Bae also served as Director of CIRNOS (2017–2024) and led JW Creagene Inc. as CEO/CTO (1998–2015), bridging science and industry. His editorial and leadership roles include Editor-in-Chief of the Journal of Bacteriology and Virology, President of the Korean Society of Virology, and Vice President of the Korean Vaccine Society. His diverse roles demonstrate a unique blend of academic excellence, organizational leadership, and translational research expertise.

🔍 Research Focus:

Dr. Yong-Soo Bae’s research focuses on innate and adaptive immune regulation, tumor immunology, mucosal immunotherapy, and vaccine delivery. He investigates cellular interactions in the immune microenvironment, with particular attention to innate lymphoid cells (ILCs), neutrophils, and dendritic cells. His translational work includes novel vaccine platforms, epitranscriptomics, immune checkpoint modulation (e.g., CISH, PD-1), and cell therapy for diseases such as asthma, leukemia, and cancer. He also explores microbiome-immune crosstalk and inflammation-related organ damage (e.g., renal fibrosis, lung inflammation). His group has published extensively on m6A modifiers, microRNAs, and innovative delivery systems like gel-to-nanovaccines. His latest studies dive into immunometabolism and the interplay between immune cells and tissue repair, offering groundbreaking insights for future immunotherapies. Dr. Bae’s work is highly cited and remains at the forefront of immune system-based therapeutic innovation.

📚 Publications Top Notes:

  1. 📘 Therapeutic Potential of microRNA Against Th2-associated Immune Disorders – Current Topics in Medicinal Chemistry (2021)

  2. 💉 COVID-19 Vaccines and Oral-Mucosal Vector System as a Potential Vaccine Platform – Vaccines (2021)

  3. 🧬 Immunotherapeutic Potential of m6A-Modifiers and microRNAs in AML – Biomedicines (2021)

  4. 🎯 Epitranscriptomic Approach to Improve ICB Therapy by Targeting CISH – Cells (2021)

  5. 🧫 TFH-B-TRM Dysregulation and Anti-PD-1 Responses in EGFR-mutant Lung Cancer – Nature Communications (2021)

  6. 🧪 Adenoviral CD200R-Ig Enhances Antitumor Immunity via M2 Macrophage Inhibition – Molecular Therapy

  7. 🌫 Air Pollutant-induced Neutrophils Worsen Airway Inflammation – JACI (2021)

  8. 🦠 NCR+ILC3s and the Microbiome in Asthma Severity – Immune Network (2021)

  9. 📖 Advances in Personalized Therapy for AML by Targeting Intracellular Checkpoints – eBook Chapter (2021)

  10. 🧵 Siglec-F Neutrophils Drive Fibrosis in Renal Disease – JCI (2022)

🧾 Conclusion:

Dr. Yong-Soo Bae is an exceptional and highly deserving candidate for the Best Researcher Award. His contributions over four decades span foundational research, translational innovation, academic leadership, and scientific diplomacy. The depth of his scientific output, particularly in immunology, epigenetics, and vaccine development, is matched by his long-term commitment to mentoring, editorial work, and building research institutions in Korea.While enhancing his global recognition and expanding international collaborative outputs could further elevate his status, Dr. Bae’s consistent high-impact contributions, research leadership, and policy involvement clearly position him as a top-tier researcher in the life sciences.

Fani Pantouli | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Dr. Fani Pantouli | Immunology Cellular Interactions | Best Researcher Award

Dr. Fani Pantouli, Cleveland Clinic Florida Research and Innovation Center, United States

Dr. Fani Pantouli is a passionate and results-driven research scientist with deep expertise in neuroscience, pharmacology, immunology, and oncology. A USA permanent resident, she currently serves as a Postdoctoral Fellow at the Cleveland Clinic Florida Research and Innovation Center. Her work bridges cutting-edge vaccine development and cancer therapeutics, contributing significantly to preclinical and translational research. Dr. Pantouli’s scientific approach blends in vivo and in vitro techniques to uncover therapeutic pathways, particularly in head and neck cancer and viral immunology. Her interdisciplinary knowledge is reflected in a growing portfolio of peer-reviewed publications addressing pressing biomedical challenges, from COVID-19 immunity to neuropsychiatric disorders. She is known for her innovative methodologies, collaborative mindset, and unwavering dedication to advancing human health. Dr. Pantouli’s work is making a meaningful impact on personalized medicine and translational therapeutics, positioning her as a rising leader in biomedical research.

Publication Profile: 

Orcid

✅ Strengths for the Award:

  1. Multidisciplinary Expertise
    Dr. Pantouli integrates neuroscience, immunology, pharmacology, and oncology into her research, making her contributions uniquely cross-disciplinary and impactful.

  2. High-Impact Research in Vaccine Development
    Her postdoctoral work on COVID-19 and respiratory viruses, particularly her development of T-cell profiling and viral neutralization assays, directly informs global efforts in personalized vaccine design.

  3. Innovative Cancer Models
    She developed a novel in vivo murine model for head and neck squamous cell carcinoma, advancing drug screening for p53-related targets. This is vital in understanding and treating cancers with p53 mutations.

  4. Robust Publication Record
    Dr. Pantouli has authored or co-authored multiple peer-reviewed articles in reputable journals (e.g., Vaccines, Neuropsychopharmacology), with several under review in top-tier outlets like Science and Journal of Biological Psychiatry.

  5. Focus on Health Equity
    Her research into ethnic differences in immune response underscores a strong commitment to inclusive and equitable healthcare.

  6. Experience in Preclinical & Translational Research
    Her hands-on experience building disease models and testing therapeutic strategies bridges basic science and clinical application—core to translational medicine.

⚠️ Areas for Improvement:

  1. Independent Research Leadership
    While she has made significant contributions as a postdoctoral fellow, moving toward independent investigator roles (e.g., PI on grants) would strengthen her candidacy.

  2. Visibility and Recognition
    Increased presence in international symposia, keynote talks, or award recognitions would help boost her visibility within the scientific community.

  3. Mentorship and Community Involvement
    Involvement in mentoring junior researchers or leading educational outreach initiatives could further showcase her leadership potential.

🎓 Education:

Dr. Pantouli holds a Ph.D. in Neuropharmacology from the University of Surrey and St. George’s University of London, awarded between 2014 and 2017. Her doctoral studies explored neural mechanisms underpinning pharmacological and behavioral outcomes, laying a solid foundation for her current work in translational medicine. Prior to her Ph.D., she completed an MSc in Molecular Neuroscience from the University of Bristol in 2011, where she specialized in neurodevelopmental and degenerative disorders. Her undergraduate studies were completed at the University of Bedfordshire in 2010, where she earned a BSc (Hons) in Biomedical Science. Dr. Pantouli’s academic trajectory reflects a commitment to interdisciplinary learning and a focus on brain and immune system interactions. Her education combines rigorous training in molecular biology, pharmacology, and neuroscience, empowering her to address complex biomedical questions with a systems-level perspective.

🧪 Experience:

Dr. Pantouli is currently a Postdoctoral Fellow in Vaccine Development Research at the Cleveland Clinic Florida Research and Innovation Center (June 2023 – Present), where she investigates T cell immune responses and develops viral neutralization assays for respiratory viruses including SARS-CoV-2. Previously, she was a Postdoctoral Fellow in the Cancer Research Lab at the same institute (January 2022 – June 2023), where she created innovative murine models of head and neck cancer to evaluate therapeutic efficacy targeting mutant p53. Her research integrates advanced in vivo systems and immune profiling to enhance drug discovery and vaccine evaluation. With a decade-long track record across academia and clinical research centers, Dr. Pantouli has developed robust platforms for translational research, immunotherapeutics, and precision medicine. Her skills span experimental design, animal modeling, immunoassays, and bioanalysis, equipping her to tackle critical gaps in infectious disease and oncology treatment strategies.

🔬 Research Focus:

Dr. Pantouli’s research is centered on translational medicine, focusing on vaccine development, immunotherapy, and molecular pharmacology. Her current projects address immune modulation in viral infections, especially COVID-19, and the development of preclinical assays for vaccine and drug evaluation. She also leads research in oncology, particularly targeting p53 mutations in head and neck squamous cell carcinoma using in vivo models. Her earlier academic work examined the neural and behavioral effects of neuropeptides and receptor modulators in models of autism and Fragile X Syndrome, showing a consistent interest in neuroimmune interactions. She employs a multidisciplinary approach—blending pharmacological, molecular, and immunological tools—to explore how targeted therapies can be optimized for diverse populations. Her work is vital for advancing personalized medicine, especially for aging populations and ethnically diverse cohorts, where vaccine efficacy and immune response can differ significantly.

📚 Publications Top Notes:

  • 🧫 Ethnic differences in COVID-19 T cell immunity responses across variants from Wuhan to Omicron – Accepted in Vaccines

  • 🧠 Evaluation of SR-17018 and oxycodone in the conditioned place preference paradigm using peanut butter chip vehicle – In preparation, Neuropharmacology

  • 🧬 Generation of antigen-specific paired heavy-light chain antibody sequences using large language models – Submitted to Science

  • 💉 COVID-19 Vaccination Enhances the Immunogenicity of Seasonal Influenza Vaccination in the Elderly – Vaccines (2025)

  • 🧩 Tilted striatofugal balance and mGluR4 modulation in the Fmr1 mouse model of Fragile X Syndrome – Under review, Journal of Biological Psychiatry

  • 👃 Acute, chronic and conditioned effects of intranasal oxytocin in mu opioid receptor knockout mice: social context matters – Neuropsychopharmacology (2024)

🧾 Conclusion:

Dr. Fani Pantouli is a highly promising and impactful scientist whose research spans some of the most critical health challenges of our time—infectious diseases, cancer, and neurodevelopmental disorders. Her technical expertise, innovative model development, and deep understanding of immune and neural systems make her an excellent nominee for the Best Researcher Award.

Miriam Götte | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Assist. Prof. Dr. Miriam Götte | Immunology Cellular Interactions | Best Researcher Award

Assist. Prof. Dr. Miriam Götte , Westdeutsches Tumorzentrum, Universitätsklinikum Essen , Germany

Dr. Miriam Götte is a leading expert in exercise and movement science in oncology, currently affiliated with the University Hospital Essen. With a dedicated focus on pediatric and young adult cancer care, she has led numerous interdisciplinary initiatives combining sports science, immunology, and oncology. As head of the Working Group on Sports and Movement Therapy at the West German Tumor Center, she has pioneered therapeutic interventions improving the quality of life in cancer patients. Dr. Götte holds a habilitation in Movement Science in Oncology and has been a postdoctoral researcher since 2014. Her work has been recognized nationally and internationally through prestigious awards. Passionate about improving survivorship care, she integrates clinical research, physical rehabilitation, and academic leadership. Alongside her academic career, she balances motherhood, having taken two parental leaves, which reflects her ability to manage demanding roles in both personal and professional spheres.

Publication Profile:

Scopus

✅ Strengths for the Award:

  1. 🌍 Leading Expertise in Exercise Oncology: Dr. Götte has made outstanding contributions to the field of exercise-based interventions in pediatric and adolescent oncology, a highly impactful and emerging research domain.

  2. 📊 Rich and Relevant Research Output: With over 10 peer-reviewed publications in top-tier journals (2023–2024 alone), she is actively contributing novel data, especially around HIIT, immune response, stem cell transplantation, and survivorship care.

  3. 👩‍🔬 Translational Focus with Real-World Impact: Her work bridges clinical research and applied therapy, ensuring that findings benefit patient quality of life and recovery during and after cancer treatment.

  4. 🤝 National Leadership and Collaborations: As Head of the Working Group on Sports and Movement Therapy and a core member of the ActiveOncoKids Network, she leads national initiatives and cross-border collaborations.

  5. 🏆 Recognized with Prestigious Awards: Awards such as the MASCC Young Investigator Award (2015) and Best Abstract at ASORS (2017) reflect her high academic standing and the relevance of her research.

  6. 📚 Interdisciplinary Approach: Combining sports science, immunology, pediatrics, and education, she exemplifies a multidisciplinary perspective that advances both research and therapeutic care.

⚙️ Areas for Improvement:

  1. 📣 Global Visibility: While well-known in German-speaking countries and European forums, increasing participation in global oncology or exercise medicine symposia (e.g., ASCO, ACSM) would raise international recognition.

  2. 💼 Expanded Mentorship: Publishing with more junior researchers as first authors could further support the next generation and solidify her legacy as a mentor in her field.

  3. 🌐 Broader Public Engagement: Developing online modules, webinars, or patient-facing tools (especially for young survivors) could enhance public awareness and dissemination of her impactful work.

🎓 Education:

Dr. Miriam Götte has a solid academic background in sports and medical sciences. She began her academic journey studying Sports Science with a focus on prevention and rehabilitation at the University of Cologne from 2006 to 2010. During this period, she also pursued studies in Educational Sciences. She advanced to a doctoral program in Medical Sciences at the University of Duisburg-Essen, completing it between 2010 and 2014 under the mentorship of Prof. Dr. Dirk Reinhardt. Her academic accomplishments culminated in a habilitation in “Movement Science in Oncology” at the Medical Faculty of the University of Duisburg-Essen in 2022. This advanced qualification marks her as an expert in the interplay of exercise and oncology, particularly for pediatric and adolescent populations. Her academic path has been underpinned by a strong interdisciplinary approach, combining sports science, oncology, and education to support patients holistically.

💼 Experience:

Dr. Götte’s professional journey began at the Department of Pediatrics III, University Hospital Essen, where she worked from 2010 to 2014 during her doctoral training. She later became head of Sports and Exercise Therapy at the West German Tumor Center (2014–2017) and continued in leadership roles at the same institution until July 2023. Since January 2023, she has served as head of the Working Group on Sports and Movement Therapy in Oncology, playing a pivotal role in the ActiveOncoKids Center Ruhr. Dr. Götte also coordinated teacher training modules in Spanish and led national collaborations to develop exercise strategies during cancer treatment. She has taken two parental leaves (2017–2018 and 2023–2024), highlighting her balance between research and personal life. Her hands-on leadership in multi-center projects and her dedication to integrating physical activity into oncology care make her a driving force in supportive cancer therapy.

🏆 Awards and Honors:

Dr. Miriam Götte has received numerous awards recognizing her impactful research and leadership. She was honored with the Young Investigator Award of the Year at the MASCC/ISOO Annual Meeting on Supportive Care in Cancer in 2015. Her work on adolescent cancer care earned the Best Abstract Award at the 5th ASORS Congress in 2017. She was selected for the prestigious Josepha and Charlotte von Siebold Habilitation Support Program (2018–2019), and later received support from the Corona Care in Medicine Program (2020–2021) by the Medical Faculty of the University of Duisburg-Essen. These accolades underline her academic excellence and leadership in movement science and oncology. Dr. Götte’s pioneering research continues to shape exercise-based cancer therapy, especially for children and adolescents, earning her national and international recognition as a forward-thinking clinician-scientist.

🔬 Research Focus:

Dr. Miriam Götte’s research revolves around exercise oncology, with a strong emphasis on pediatric and adolescent cancer patients. Her primary interest lies in exploring how physical activity interventions, particularly high-intensity interval training (HIIT), influence immune function, physical fitness, and quality of life during and after cancer therapy. She investigates the physiological and psychological impacts of exercise throughout different treatment phases, including stem cell transplantation. Her work contributes significantly to the emerging field of supportive oncology, where movement-based interventions are tailored to patient needs. Dr. Götte is also a central figure in the ActiveOncoKids network, enhancing access to structured physical activity across German-speaking countries. With a translational approach, her research bridges clinical care, immunological assessments, and rehabilitative exercise programs. Her focus is not only scientific but also deeply patient-centered, advocating for movement as a form of healing and empowerment in cancer survivorship.

📚 Publications Top Notes:

  1. 🏋️‍♂️ High-Intensity Interval Training Boosts Immune Cells in Advanced Cancer Patients and Healthy Controls – Cancer Medicine (submitted)

  2. 🧬 Impact of a Single HIIT Session on NK Cells and ILCs in Adolescents Undergoing Cancer Treatment – BMC Cancer (minor revision)

  3. 🌟 YOUEX: Longitudinal Effects on Quality of Life in Young Adults with Cancer – JAYAO (submitted)

  4. 💪 Low vs. Moderate Intensity Exercise in Pediatric Allo-HSCT Recovery – ANIMAL – Pediatric Blood & Cancer (submitted)

  5. 👶 Physical Activity Behaviors in Childhood Cancer Survivors – J Cancer Survivorship (2024)

  6. 🧒 ActiveOncoKids: Centralized Physical Activity Counseling During Oncology – Klinische Pädiatrie (2024)

  7. 🏃 Severely Reduced Physical Performance at Stem Cell Transplant Admission – BMJ Open Sport Exerc Med (2024)

  8. 🧘 P-move: RCT of Exercise in Pancreatic or Biliary Tract Cancer – Supportive Care in Cancer (2024)

  9. 🌿 Exercise Therapy in Oncology: Impact on Quality of Life and Side Effects – Dtsch Arztebl Int (2024)

  10. 🧑‍⚕️ Adaptation of Pediatric Exercise Programs During COVID-19 in Germany – Frontiers in Pediatrics (2024)

🧾 Conclusion:

Dr. Miriam Götte is highly suitable and deserving of the Best Researcher Award. Her focused and prolific research on the role of physical activity in pediatric and adolescent oncology, combined with her leadership in clinical and academic settings, sets her apart as a pioneer in supportive cancer care. She demonstrates a rare combination of scientific rigor, patient-centeredness, and organizational leadership. With strategic expansion of her international visibility and mentoring activities, she is positioned to become one of the global leaders in exercise oncology.

Muhammad Junaid Anwar | Immunology Cellular Interactions | Best Researcher Award

Published on by Cell Biologist

Mr. Muhammad Junaid Anwar | Immunology Cellular Interactions | Best Researcher Award

Mr. Muhammad Junaid Anwar , Bahauddin Zakariya Univeristy Multan Pakistan , Pakistan

Dr. Muhammad Junaid Anwar is a dedicated food scientist specializing in Food Science and Technology. With a Ph.D. from Bahauddin Zakariya University (BZU), Multan, he has established himself as a researcher with expertise in food safety, nanotechnology, and functional foods. His work focuses on developing innovative solutions for food security, nutrition, and disease prevention. Having authored multiple high-impact research publications, Dr. Anwar’s contributions span across nanotechnology-based food encapsulation, food safety enhancement, and alternative protein sources. He has also participated in prestigious conferences and workshops, further showcasing his commitment to advancing food science. His research has significantly contributed to tackling food-related health challenges such as cow milk allergies, microbial contamination, and nutraceutical applications. With his profound knowledge, industry experience, and research excellence, Dr. Anwar stands out as a promising scholar in the field. His dedication to food innovation makes him a deserving candidate for the Best Researcher Award.

Publication Profile: 

Scopus

Strengths for the Award

  1. Strong Academic Background – Dr. Muhammad Junaid Anwar has an exceptional academic record with a Ph.D. in Food Science and Technology, a strong CGPA, and an extensive research focus.

  2. High-Impact Research Publications – He has authored multiple research articles in reputable, high-impact factor journals (Ultrasonics Sonochemistry, Food Science & Nutrition, Food Bioscience, etc.). His contributions cover diverse areas, including nanotechnology, food safety, and immunomodulation.

  3. Diverse Research Contributions – His research spans crucial topics such as nano-encapsulation, diabetes management, functional foods, and nutraceuticals, demonstrating interdisciplinary expertise.

  4. Industry Experience – His experience as an Officer in Quality Enhancement and Laboratory at S.M. Food Makers highlights his applied knowledge and practical contribution to food science.

  5. Conference Participation – He has actively contributed to scientific discussions through multiple national conferences, particularly on food security and food safety.

  6. Published Abstracts & Workshops – His engagement in published abstracts and workshops reflects an effort to bridge academia with real-world food technology applications.

Areas for Improvement

  1. International Collaboration – While his research is strong, expanding collaborations with international institutions and researchers could further enhance global impact.

  2. Patent & Commercialization – Translating research into patents or commercial food innovations would strengthen his practical contributions to the industry.

  3. Citations & Recognition – As some of his latest research articles have yet to gain citations, increasing visibility through academic networks and outreach can boost recognition.

Education:

Dr. Muhammad Junaid Anwar has an exceptional academic background in Food Science and Technology. He is currently completing his Ph.D. (2021-2025) at the Department of Food Science and Technology, BZU Multan, with a stellar CGPA of 3.87/4.00. Previously, he completed his M.Sc. (Hons.) in Food Science & Technology (2018-2020) from the same institution, securing a CGPA of 3.76/4.00. His undergraduate journey began with a B.Sc. (Hons.) in Agriculture (Food Science & Technology) (2014-2018), again with a CGPA of 3.76/4.00. His solid foundation in sciences started with F.Sc. (Pre-Medical) in 2014 from Muslim Public Higher Secondary School, Multan, achieving 840/1100 marks, followed by Matriculation in 2012 from Govt. M.A Jinnah High School, Multan, with 863/1050 marks. His consistent academic excellence highlights his dedication to food science research and technological advancements, making him a strong candidate for the Best Researcher Award.

Experience:

Dr. Muhammad Junaid Anwar has a diverse professional background in food science research and industry. He completed a 7-week internship at Bunny’s Limited, Lahore, where he gained hands-on experience in food processing and quality control. He later served as an Officer (Quality Enhancement and Lab) at S.M. Food Makers for two years (2018-2020), where he worked on ensuring food safety standards and enhancing product quality. His industry experience has provided him with a deep understanding of food technology applications, quality assurance, and research methodologies. In addition to his industry roles, he has contributed to academia through extensive research on food nanotechnology, functional foods, and microbial safety. His experience spans both applied and theoretical research, making him an asset to the food science community. His professional achievements, combined with his research excellence, make him a strong contender for the Best Researcher Award.

Research Focus:

Dr. Muhammad Junaid Anwar’s research revolves around food nanotechnology, functional foods, and food safety. His recent work focuses on the nano-encapsulation of bioactive compounds, such as casein-based encapsulation for managing cow milk allergies. His contributions extend to food safety enhancements using ultrasonication and calcium chloride treatments to reduce microbial contamination in fresh produce. Dr. Anwar has also explored the nutraceutical applications of medicinal plants like fenugreek and Tribulus terrestris to develop functional foods with health benefits. His studies have highlighted the role of alternative protein sources, such as Moringa oleifera-derived proteins, in plant-based meat substitutes. Additionally, he has worked on the impact of ozone treatment in mitigating mycotoxin contamination in food. His multi-disciplinary approach to food science integrates biotechnology, food engineering, and health sciences, making his research valuable for global food security and human health. His outstanding contributions make him a strong candidate for the Best Researcher Award.

Publications Top Notes:

📌 Casein-Based Nano-Encapsulation for Cow Milk Allergy Management 🥛🔬 (Food Bioscience, 2025)
📌 Ultrasonication & Calcium Chloride Pre-Treatment for Microbial Load Reduction in Carrots 🥕🦠 (Ultrasonics Sonochemistry, 2025)
📌 Isoflavones: Natural Agents for Cancer Prevention & Treatment 🎗️🍃 (Food Science & Nutrition, 2025)
📌 Functional Yogurt with Cinnamon & Stevia for Diabetes Management 🍦🍯 (Food & Agricultural Immunology, 2024)
📌 Nutritional & Physico-Chemical Profiling of Tribulus terrestris for Nutraceutical Applications 🌿💊 (Journal of Population Therapeutics & Clinical Pharmacology, 2024)
📌 The Multifaceted Potential of Fenugreek Seeds in Health & Nanotechnology 🌱⚗️ (Food Science & Nutrition, 2024)
📌 Protein Extraction from Moringa Leaves as a Plant-Based Meat Alternative 🍃🥩 (Regulatory Toxicology & Pharmacology, 2024)
📌 Role of Ozone in Mycotoxin Management for Food Safety ⚡🍞 (PSFST Conference, 2023)
📌 Potential of Anaerobic Digestion in Food Waste Management 🔄♻️ (PSFST Conference, 2023)
📌 Addressing Food Price Fluctuations: A Global Priority 📈🌍 (PSFST Conference, 2023)
📌 Strengthening Local Food Systems for Food Security 🌾🍽️ (PSFST Conference, 2023)

Conclusion:

Dr. Muhammad Junaid Anwar has demonstrated exceptional research contributions in food science, particularly in functional foods, nanotechnology, and food safety. His high-impact publications, active participation in conferences, and industry experience make him a strong candidate for the Best Researcher Award. Strengthening international collaborations and focusing on patents or commercialization could further enhance his research impact.

Gary Chan | Host-Pathogen Interactions | Best Researcher Award

Published on by Cell Biologist

Dr. Gary Chan | Host-Pathogen Interactions | Best Researcher Award

Dr. Gary Chan , SUNY Upstate Medical University , United States

Dr. Gary Ching-Tao Chan is a distinguished professor in the Department of Microbiology and Immunology at SUNY Upstate Medical University, Syracuse, NY. He completed his Ph.D. in Immunology at the University of Alberta, Canada, under the supervision of Dr. Larry J. Guilbert. Dr. Chan’s research expertise lies in viral immunology, particularly in human cytomegalovirus (HCMV) and dengue virus (DENV). He has a robust research portfolio with numerous contributions to the field, focusing on viral-host interactions and immune modulation. His work has led to groundbreaking discoveries in HCMV pathogenesis, including viral modulation of autophagy and cell signaling pathways. Dr. Chan has held academic appointments at prestigious institutions, including Louisiana State University Health Science Center, where he contributed significantly to advancing viral immunology. His commitment to research excellence is reflected in his impactful publications and active grant support.

Publication Profile: 

Orcid

Strengths for the Award:

  1. Prolific Research Contributions: Dr. Gary Chan has made significant contributions to the field of microbiology, particularly in the understanding of human cytomegalovirus (HCMV) and its complex interactions with the immune system. His work has been consistently published in top-tier peer-reviewed journals such as Journal of Virology, Antiviral Research, and mBio, highlighting his influence in virology.

  2. Innovative and High-Impact Research: Dr. Chan’s research addresses fundamental aspects of viral pathogenesis, focusing on viral-host interactions, immune modulation, and viral replication. His innovative exploration into the molecular mechanisms of HCMV, such as the modulation of mTORC1 and the role of host transcription factors like HSF1, is groundbreaking and provides valuable insights for potential therapeutic strategies. His studies have also demonstrated significant contributions in understanding how viruses, including HCMV and Dengue virus, alter host cell signaling pathways, making his work crucial in antiviral research.

  3. Successful Grant Support: Dr. Chan has received substantial funding for his research, including multiple NIH R01 grants. His current projects, such as targeting the nuclear HSF1 for anti-HCMV strategies, are promising avenues for the development of novel antiviral therapies, further solidifying his standing as a leading researcher in his field.

  4. Recognition by Peers and Journals: His work has been widely recognized by peers in the field, as evidenced by the Journal of Virology Editor’s Pick in 2024 and the Journal of Virology Spotlight Article of Significant Interest in 2020. These accolades underline the impact and relevance of his research.

  5. Mentorship and Academic Leadership: As a Professor at SUNY Upstate Medical University, Dr. Chan contributes significantly to the academic and professional development of students and colleagues alike. His role in shaping the next generation of researchers, combined with his leadership in the field, highlights his commitment to advancing science.

Areas for Improvement:

  1. Broader Impact Across Other Virus Families: While Dr. Chan’s research on HCMV is groundbreaking, exploring the broader spectrum of viral infections, including RNA viruses like SARS-CoV-2, could expand his impact across viral disease research. By diversifying his focus, he could address other significant public health threats, further enhancing the breadth of his research.

  2. Increased Interdisciplinary Collaboration: Although Dr. Chan has successfully collaborated with various experts in the field of virology, fostering interdisciplinary collaborations with researchers from fields such as bioinformatics, computational biology, and structural biology could accelerate the development of novel antiviral therapies and improve the understanding of viral mechanisms.

  3. Public Engagement and Communication: Dr. Chan’s impactful research is highly technical, and while it has contributed to the scientific community, increased efforts in communicating his findings to the broader public could help in promoting awareness of viral infections and their treatment. Public engagement through media, outreach programs, or collaborative projects with health organizations could amplify his work’s societal impact.

Education:

Dr. Gary Chan earned his Ph.D. in Immunology from the University of Alberta, Edmonton, Canada, from 1999 to 2005. His doctoral research focused on “Human cytomegalovirus-induced trophoblast apoptosis,” under the mentorship of Dr. Larry J. Guilbert in the Department of Medical Microbiology and Immunology. Following his Ph.D., Dr. Chan pursued postdoctoral training at Louisiana State University Health Science Center (2006–2011) in the Department of Microbiology and Immunology. Under the guidance of Dr. Andrew Yurochko, his postdoctoral research expanded his expertise in virology and immune modulation. Dr. Chan’s extensive academic background, coupled with his training in cutting-edge viral immunology, has laid the foundation for his pioneering work on viral-host interactions, particularly with human cytomegalovirus (HCMV), contributing to novel therapeutic strategies.

Experience:

Dr. Gary Chan is a Professor at the Department of Microbiology and Immunology at SUNY Upstate Medical University, a role he has held since 2023. Prior to this, he was an Associate Professor at the same department from 2018 to 2023. Dr. Chan has a wealth of experience in virology and immunology, with a focus on human cytomegalovirus (HCMV) and dengue virus (DENV). He has been instrumental in advancing research on the molecular mechanisms of viral infections and their impact on the host immune system. Dr. Chan’s academic journey includes several years of postdoctoral training at Louisiana State University, where he contributed to significant findings in viral replication and immune responses. With a comprehensive background in molecular virology, cell biology, and immunology, Dr. Chan is recognized for his expertise in viral pathogenesis and therapeutic research.

Awards and Honors:

Dr. Gary Chan has received numerous prestigious awards and recognitions for his research excellence. In 2024, his publication, Human cytomegalovirus modulates mTORC1 to redirect protein translation within quiescently infected monocytes, was selected as an Editor’s Pick by the Journal of Virology. Additionally, his article on HCMV-induced autophagy preventing necroptosis of infected monocytes was featured as a Spotlight Article of Significant Interest in 2020. His innovative research has earned him continuous recognition within the virology community, including numerous peer-reviewed publications. Dr. Chan’s research contributions have also attracted substantial NIH grant support, including an R01 from the NIAID, to explore novel anti-HCMV strategies targeting nuclear HSF1. His scholarly achievements, including the successful funding of multi-year research projects, underscore his dedication to advancing our understanding of viral diseases and their immune modulation.

Research Focus:

Dr. Gary Chan’s research primarily focuses on viral immunology, specifically human cytomegalovirus (HCMV) and dengue virus (DENV). His work explores how these viruses manipulate host cellular processes, such as signaling pathways and immune responses, to promote viral replication and persistence. One of his major research areas is investigating the interactions between HCMV and monocytes, particularly how the virus modulates autophagy and apoptosis to avoid immune detection and promote its survival. Additionally, Dr. Chan’s research delves into the role of host transcription factors, such as HSF1, in regulating viral replication. His innovative work also involves creating bioswitches through protein and DNA engineering to combat HCMV. Through these projects, Dr. Chan aims to identify novel therapeutic targets to limit viral infections and improve antiviral strategies. His work is pivotal in advancing the understanding of how viral infections impact the host immune system and contribute to disease pathogenesis.

Publications Top Notes:

  1. Targeting HSF1 prevents HCMV replication 🦠

  2. DENV infection induces differential immunotranscriptomic profiles 🦟

  3. B cell receptor enhancement of dengue virus infection 🧬

  4. Virion-associated US28 modulates Akt activity in monocytes 💉

  5. The harms of promoting the leak lab hypothesis for SARS-CoV-2 🧫

  6. HCMV modulates mTORC1 in infected monocytes 💪

  7. Virology – The path forward 🔬

  8. Inhibition of SIRT2 promotes HCMV-infected monocyte death ⚔️

  9. Virology under the Microscope – A call for rational discourse 📚

  10. Modulation of host cell signaling in HCMV latency 🧪

Conclusion:

Dr. Gary Ching-Tao Chan is highly deserving of the Best Researcher Award due to his outstanding contributions to the field of virology, particularly in the area of human cytomegalovirus and its interaction with the immune system. His innovative research has shaped the understanding of viral pathogenesis, leading to potential therapeutic breakthroughs. With significant funding, prestigious recognition, and a strong academic presence, Dr. Chan continues to push the boundaries of scientific knowledge. While there are opportunities for expansion into other viral research areas and greater public outreach, his accomplishments make him a leading figure in microbiology and an excellent candidate for this award.